Screening and Prevention

 

Screening

Screening tests can be useful for detecting certain types of cancer at an early stage. However, no screening tests can find laryngeal or hypopharyngeal cancer early. The best way to make sure that your cancer is treated at the earliest possible stage, when it is most curable, is to ask your doctor as soon as you notice potential signs or symptoms of the disease.

Prevention

Most cases of laryngeal and hypopharyngeal cancers can be prevented by avoiding the factors that are known to increase the risk of these diseases, especially tobacco and alcohol.

  • Alcohol - If you drink alcohol (especially beer and hard liquor), limit the number of drinks you have.
  • Diet - The American Cancer Society recommends that everyone eat a variety of healthy food, especially food that come from plants. You should eat at least five servings of fruits and vegetables every day, as well as whole-grain food. Eating food that is rich in vitamin A (found in carrots, sweet potatoes, and other colored vegetables) and vitamin E (found in certain nuts, seeds, and vegetables) might also help prevent laryngeal and hypopharyngeal cancers.
  • Tobacco - If you smoke cigarettes, cigars, or pipes or use smokeless tobacco, quit. This is the most effective way to prevent laryngeal and hypopharyngeal cancers. Even if you have smoked for years, quitting can reduce your risk of getting these diseases.
  • Ventilation at work - If you work with chemicals that increase the risk of laryngeal and hypopharyngeal cancers, your workplace needs plenty of ventilation.

This content has been reviewed and approved by Myo Thant, MD.

This content was last modified on November 12, 2007 .
Latest Cancer News
Radiofrequency Ablation Effective For Small Renal Cell Carcinoma and Other Masses

March 11, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that radiofrequency ablation (RFA) is effective treatment for patients with renal masses, including renal cell carcinoma (RCC). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Single-dose Neulasta® as Effective as Multiple-dose Neupogen® in Children with Sarcoma

March 11, 2010 — Researchers involved in an international multicenter randomized trial have reported that single-dose Neulasta® (pegfilgrastim) is as effective as multiple-dose Neupogen® (filagrastim) for support of children receiving intensive chemotherapy for previously treated sarcoma. The details of this study were published in the March 10, 2010 issue of the Journal of Clinical Oncology.

Updated Survival Data on Provenge® for Treatment of Hormone Refractory Prostate Cancer Presented

March 11, 2010 — Researchers affiliated with the IMPACT trial have reported that additional follow-up and more analyses demonstrate a clear survival advantage of Provenge® (sipuleucel-T) versus placebo in men with hormone-refractory prostate cancer. The details of this study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco between March 5 and 7.

Select news items provided by Reuters Health
Risk & Prevention